Beyond ten cycles of cabazitaxel for castrate-resistant prostate cancer.
Indian J Cancer
;
2014 Jul-Sep; 51(3): 363-365
Artículo
en Inglés
| IMSEAR
| ID: sea-154420
ABSTRACT
Background:
There are limited data regarding cabazitaxel use beyond 10 cycles. Patients andMethods:
Retrospective analysis of prospectively collected data of patients with metastatic castrate-resistant prostate cancer who received over 10 cycles of cabazitaxel after docetaxel failure.Results:
Four patients received between 14 and 27 cycles. Reasons for stopping cabazitaxel were toxicity (2), progression (1) and logistics (1). Two of the three patients with measurable disease attained a partial remission (PR). Three patients continued to have a PSA response after 10 cycles; PSA nadir occurred between 17 and 23 cycles. Other than peripheral neuropathy (PN), all the cabazitaxel-related toxicities occurred after the initial cycles and did not increase cumulatively. Clinically significant neuropathy occurred after 15-17 cycles. The cabazitaxel-induced PN was partially reversible, with improvement from grade 3 to grade 2 after a 3-5-month long drug holiday.Conclusion:
Cautiously continuing cabazitaxel until progression or intolerable toxicity may maximize efficacy.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Asunto principal:
Piridazinas
/
Humanos
/
Esquema de Medicación
/
Enfermedades del Sistema Nervioso Periférico
/
Quimioterapia
/
Neoplasias de la Próstata Resistentes a la Castración
Idioma:
Inglés
Revista:
Indian J Cancer
Año:
2014
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS